Pfizer and biontech receive u.s. fda approval & authorization for omicron kp.2-adapted covid-19 vaccine

New york & mainz, germany--(business wire)--pfizer inc. (nyse: pfe, “pfizer”) and biontech se (nasdaq: bntx, “biontech”) today announced that the u.s. food and drug administration (“fda”) has approved the supplemental biologics license application for individuals 12 years of age and older (comirnaty® (covid-19 vaccine, mrna), and granted emergency use authorization for individuals 6 months through 11 years of age (pfizer-biontech covid-19 vaccine) of the companies' omicron kp.2-adapted 2024-202.
BNTX Ratings Summary
BNTX Quant Ranking